CALGARY, March 4, 2014 /PRNewswire/ – Dr. Brad Thompson, President and CEO of
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in
the 34th Annual Cowen and Company Healthcare Conference in a session on Wednesday March 5th, 2014 at 8:40 a.m. ET. The conference takes place from March 3rd to 5th at the Boston Marriott Copley Place in Boston, MA.
A live audio link to the webcast session will be available at: http://wsw.com/webcast/cowen16/ONCY or on the company’s website at www.oncolyticsbiotech.com/for-investors/presentations. It is recommended that listeners log on 10 minutes in advance of a
live session to register and download any necessary software. An audio
replay will be accessible approximately two hours following the
presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics’ clinical program includes a variety of human trials
including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit: www.oncolyticsbiotech.com.
The session and webcast times are subject to change. This release and
the presentation related thereto contain forward-looking statements
which involve known and unknown risks, delays, uncertainties and other
factors not under the Company’s control and which may cause actual
results, performance or achievements of the Company to be materially
different from the results, performance or expectations implied by
these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of
REOLYSIN as a cancer treatment, the success and timely completion of
clinical studies and trials, uncertainties related to the research and
development of pharmaceuticals and uncertainties related to the
regulatory process. Investors should consult the Company’s quarterly
and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements. The Company does not
undertake to update these forward-looking statements, except as
required by applicable laws.
SOURCE Oncolytics Biotech Inc.
Released March 4, 2014